Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 16/20 | 0.41 |
| ▸ | TEC | P42680 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12301252 | 0.81 | EGFR (0.48) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL4050447 | 0.76 | ADAM17 (0.49) | — | |
| SCHEMBL14591907 | 0.74 | NT5E (0.60) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL485686 | 0.74 | NT5E (0.65) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL11955074 | 0.72 | NT5E (0.57) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL27766191 | 0.72 | NT5E (0.61) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL14307070 | 0.72 | NT5E (0.57) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL4900145 | 0.71 | THRA (0.60) | NT5EEGFREPHA2KDREPHB4 | |
| SCHEMBL693400 | 0.71 | NT5E (0.55) | NT5E | |
| SCHEMBL13197081 | 0.71 | NT5E (0.56) | NT5EEGFREPHA2KDREPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6057336-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-05-02 | — | — | US | disclosed |